Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.

Goo L, VanBlargan LA, Dowd KA, Diamond MS, Pierson TC.

PLoS Pathog. 2017 Feb 16;13(2):e1006178. doi: 10.1371/journal.ppat.1006178. eCollection 2017 Feb.

2.

Recovery of West Nile Virus Envelope Protein Domain III Chimeras with Altered Antigenicity and Mouse Virulence.

McAuley AJ, Torres M, Plante JA, Huang CY, Bente DA, Beasley DWC.

J Virol. 2016 Apr 14;90(9):4757-4770. doi: 10.1128/JVI.02861-15. Print 2016 May.

3.

A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.

Lai H, Paul AM, Sun H, He J, Yang M, Bai F, Chen Q.

Vaccine. 2018 Mar 27;36(14):1846-1852. doi: 10.1016/j.vaccine.2018.02.073. Epub 2018 Feb 26.

4.
5.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2011 Jun;7(6):e1002111. doi: 10.1371/journal.ppat.1002111. Epub 2011 Jun 30.

6.

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W.

J Virol. 2017 Nov 14;91(23). pii: e01181-17. doi: 10.1128/JVI.01181-17. Print 2017 Dec 1.

7.

Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody.

Sultana H, Foellmer HG, Neelakanta G, Oliphant T, Engle M, Ledizet M, Krishnan MN, Bonafé N, Anthony KG, Marasco WA, Kaplan P, Montgomery RR, Diamond MS, Koski RA, Fikrig E.

J Immunol. 2009 Jul 1;183(1):650-60. doi: 10.4049/jimmunol.0900093. Epub 2009 Jun 17.

8.

A West Nile virus CD4 T cell epitope improves the immunogenicity of dengue virus serotype 2 vaccines.

Hughes HR, Crill WD, Davis BS, Chang GJ.

Virology. 2012 Mar 15;424(2):129-37. doi: 10.1016/j.virol.2011.12.012. Epub 2012 Jan 14.

9.

The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Lee PD, Mukherjee S, Edeling MA, Dowd KA, Austin SK, Manhart CJ, Diamond MS, Fremont DH, Pierson TC.

J Virol. 2013 Dec;87(24):13729-40. doi: 10.1128/JVI.02340-13. Epub 2013 Oct 9.

10.

DNA-immunisation with dengue virus E protein domains I/II, but not domain III, enhances Zika, West Nile and Yellow Fever virus infection.

Slon Campos JL, Poggianella M, Marchese S, Mossenta M, Rana J, Arnoldi F, Bestagno M, Burrone OR.

PLoS One. 2017 Jul 25;12(7):e0181734. doi: 10.1371/journal.pone.0181734. eCollection 2017.

11.

A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions.

Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE Jr, Pierson TC.

Nat Microbiol. 2019 Jan;4(1):71-77. doi: 10.1038/s41564-018-0283-7. Epub 2018 Nov 19.

12.

Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2.

da Silva Voorham JM, Rodenhuis-Zybert IA, Ayala Nuñez NV, Colpitts TM, van der Ende-Metselaar H, Fikrig E, Diamond MS, Wilschut J, Smit JM.

PLoS One. 2012;7(3):e29957. doi: 10.1371/journal.pone.0029957. Epub 2012 Mar 14.

13.

Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.

Budigi Y, Ong EZ, Robinson LN, Ong LC, Rowley KJ, Winnett A, Tan HC, Hobbie S, Shriver Z, Babcock GJ, Alonso S, Ooi EE.

PLoS Negl Trop Dis. 2018 Feb 9;12(2):e0006209. doi: 10.1371/journal.pntd.0006209. eCollection 2018 Feb.

14.

Role of BC loop residues in structure, function and antigenicity of the West Nile virus envelope protein receptor-binding domain III.

Zhang S, Bovshik EI, Maillard R, Gromowski GD, Volk DE, Schein CH, Huang CY, Gorenstein DG, Lee JC, Barrett AD, Beasley DW.

Virology. 2010 Jul 20;403(1):85-91. doi: 10.1016/j.virol.2010.03.038. Epub 2010 May 6.

15.

Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses.

Maillard RA, Liu T, Beasley DW, Barrett AD, Hilser VJ, Lee JC.

J Am Chem Soc. 2014 Jul 23;136(29):10315-24. doi: 10.1021/ja503318x. Epub 2014 Jul 8.

16.

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.

17.

The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS.

PLoS Pathog. 2010 Apr 1;6(4):e1000823. doi: 10.1371/journal.ppat.1000823.

18.

Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.

Vogt MR, Dowd KA, Engle M, Tesh RB, Johnson S, Pierson TC, Diamond MS.

J Virol. 2011 Nov;85(22):11567-80. doi: 10.1128/JVI.05859-11. Epub 2011 Sep 14.

20.

A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection.

Pierson TC, Sánchez MD, Puffer BA, Ahmed AA, Geiss BJ, Valentine LE, Altamura LA, Diamond MS, Doms RW.

Virology. 2006 Mar 1;346(1):53-65. Epub 2005 Dec 2.

Supplemental Content

Support Center